ProShares Ultra Nasdaq Biotechnology ETF (BIB) Jumped 1.37% on Aug 24

August 24, 2017 - By Darrin Black

Shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) last traded at 53.45, representing a move of 1.37%, or 0.72 per share, on volume of 273,304 shares. After opening the trading day at 53.31, shares of ProShares Ultra Nasdaq Biotechnology ETF traded in a close range. ProShares Ultra Nasdaq Biotechnology ETF currently has a total float of 7.90 million shares and on average sees 280,467 shares exchange hands each day. The stock now has a 52-week low of 35 and high of 60.19.

What’s Behind Germany’s Economic Growth?

Germany is the biggest economy and Europe. Globally, the nation comes next to the US and Japan. It includes in its trading lists companies like ProShares Ultra Nasdaq Biotechnology ETF. Playing an important role in this compelling feat is the German Stock Exchange, particularly its main trading index, the Deutsche Aktien Xchange (DAX) 30.

Getting to Know the German Stock Exchange

Before taking a look at DAX 30 through the years, it is first important to understand the German Stock Exchange.

It is undeniable that the German Stock Exchange is among the most influential stock exchanges in the world. It has eight components including the FWB Frankfurter Wertpapierbörse or the Frankfurt Stock Exchange, the Börse Stuttgart or the Stuttgart Stock Exchange, the Börse Berlin-Bremen, the BÖAG Börsen AG, and the Hamburger Börse or the Hamburg Stock Exchange.

The Frankfurt Stock Exchange, facilitating the trade in Frankfurt, is the biggest component of the German Stock Exchange. About 80% of the total market capitalization in Germany is listed on the Frankfurt Stock Exchange.

It is followed by the Stuttgart Stock Exchange, which lists most of the financial companies in Germany.

The Börse Berlin-Bremen, facilitating the trade in Berlin-Charlottenburg, is one of the newest stock exchanges in the world. It was founded in 2003 after the Berlin Stock Exchange and the Börse Bremen had merged.

Meanwhile, the BÖAG Börsen AG, facilitating the trade ik Hamburg and Hanover, was founded in 1999 after the Hamburg Stock Exchange and the Hanover Stock Exchange had consolidated. It allowed ProShares Ultra Nasdaq Biotechnology ETF to become in the main focus of investors.

On the other hand, the Hamburg Stock Exchange is one of the oldest stock exchanges in the world, having been founded in 1558.

DAX 30, Europe’s Finest

The DAX 30 is Germany’s benchmark equity market index. It tracks the performance of the best 30 German blue chip stocks on the Frankfurt Stock Exchange as far as market capitalization is concerned. This means that the DAX 30 is a strong indicator of how well the German economy performs and how confident investors are in the German trading environment. Being in DAX means for ProShares Ultra Nasdaq Biotechnology ETF stay in business.

The main currency on the DAX 30 is euro. Its movement is in increments of 0.50. To trade on the DAX 30, the minimum trade size required is one index while the margin requirement is commonly 2%.

Since December 31, 1987, the DAX 30 had a base value of 1,000. Equity prices are computed using XETRA, a system that has been calculating indices since June 18, 1999. XETRA had begun calculating indices every one second in January 2006.

The DAX 30 had its longest bullish period between 2003 and 2007, which lasted for exactly 1,587 days. It had attained its peak level during the said period at €8,105.69. After the 2008 Global Financial Crisis, it fell to an all-time low of €3,580 in 2009.

Nonetheless, the DAX 30 eventually recouped from the repercussions of the 2008 Global Financial Crisis. During one of its best years, the DAX 30 had recorded its all-time high of €8,736 on September 19, 2013.

Germany is surely one of the most interesting markets in the world today. Consequently, investing in DAX 30 is highly recommended for retail investors.

More notable recent ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) news were published by: Marketwatch.com which released: “ProShares UltraShort Nasdaq Biotechnology” on June 16, 2010, also Seekingalpha.com with their article: “How Prices Of ETF BIB Are Seen By Market-Makers” published on December 21, 2015, Seekingalpha.com published: “Only 9% Of Nasdaq Biotechnology Stocks Are Good Value: I Am Shorting The …” on October 07, 2015. More interesting news about ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) were released by: Etftrends.com and their article: “More Triple-Leveraged Biotech ETFs Come to Town” published on June 23, 2015 as well as Etftrends.com‘s news article titled: “As Election Day Arrives, Is It Finally Time to Buy Biotech ETFs?” with publication date: November 08, 2016.

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The ETF has market cap of $416.57 million. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. It currently has negative earnings. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.